Weller et al. substantiate the role of translation dysregulation in mediating anti-tumor immunity by demonstrating that TYW2 loss in melanoma cells induces aberrant peptide MHC presentation, increasing both tumor immunogenicity and sensitivity to ICB therapy. TYW2 expression levels in patients with melanoma predict clinical outcomes, highlighting translation regulatory factors as immunotherapy targets.

Analysis of homogeneous rejected and non-rejected melanoma tumors uncovers critical immune evasion mechanisms, identifies MIF as a key regulator, and stresses the key role of tumor-associated macropha...